ResMed develops medical devices and connected software for sleep apnea, respiratory conditions, and out-of-hospital care. It sells CPAP and bilevel therapy devices, masks, accessories, and ventilation products, alongside cloud-based software used by home medical equipment providers and care organizations. A substantial part of demand comes from recurring mask and supply replacements and patient therapy adherence.
ResMed Inc. (RMD) has a MarketKingdoms composite score of 67.5 (B), an B-range rating. It ranks 551st of 1,866 covered companies, 25th of 78 in Healthcare (sector average 64.4) and 1st of 9 in Medical Instruments & Supplies. Scores as of 2026-10-26.
Its strongest lenses are Industry opportunity at 82 (Healthcare average 81) and Catalyst watch at 81 (Healthcare average 74). Its weakest lenses are Trend (momentum) at 41 (sector average 50) and Expansion (growth) at 49 (sector average 50).
| Lens | Type | RMD | Healthcare average | Medical Instruments & Supplies average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 82 | 81 | 82 | 77th |
| Stock selection | Research signal | 80 | 79 | 78 | 54th |
| KPI momentum | Research signal | 77 | 78 | 76 | 43rd |
| Catalyst watch | Research signal | 81 | 74 | 76 | 97th |
| Price (valuation) | Fundamental lens | 49 | 50 | 49 | 47th |
| Expansion (growth) | Fundamental lens | 49 | 50 | 46 | 55th |
| Quality (profitability) | Fundamental lens | 76 | 50 | 46 | 87th |
| Trend (momentum) | Fundamental lens | 41 | 50 | 36 | 38th |
The most recent call analysed was held on 2026-08-06 (fiscal 2026 Q4). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is +6.1%: its price is above the path its market, sector and industry moves explain (overvalued versus the model path). Factor sensitivity: market beta 0.85, sector beta 0.56, industry beta 0.28; the factor model explains 25% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Intuitive Surgical Inc. (ISRG) | 66.2 | B | -11.5% |
| West Pharmaceutical Services Inc. (WST) | 65.0 | B | -25.9% |
| Becton Dickinson & Co. (BDX) | 64.4 | B | -4.6% |
| Baxter International Inc. (BAX) | 61.7 | B- | -0.9% |
| Alcon Inc. (ALC) | 61.1 | B- | -14.7% |
| Align Technology Inc. (ALGN) | 60.2 | B- | -17.5% |
| The Cooper Companies Inc. (COO) | 56.7 | C+ | -20.6% |
| Medline Inc. (MDLN) | 53.8 | C+ | -12.2% |
ResMed Inc. financial statements · Healthcare sector ranking · Medical Instruments & Supplies industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.